Abstract
BackgroundThis study was conducted to estimate the prevalence, determinants of hepatitis B, hepatitis C and the survival of tuberculosis patients until drug-induced hepatitis.MethodsProspective cohort study design was implemented. The data were collected from September 2016 – May 2019. Systematic random sampling was used to select the study participants. Baseline data were collected before the patient starts DOTS, the sign of liver toxicity was assessed every week. Tuberculosis treatment outcomes and WHO clinical stage was recorded at the end of 6th months. Descriptive statistics were used to estimate the prevalence of hepatitis B, hepatitis C viral infections and their effect on tuberculosis treatment outcomes. Binary logistic regression was used to identify the determinants of hepatitis B and C infections. The Kaplan Meier survival curve was used to estimate the survival of tuberculosis patient and Cox regression was used to identify the predictors of drug-induced hepatitis.ResultsA total of 3537 tuberculosis patients were followed. The prevalence of hepatitis B and C viral infection among tuberculosis patients were 15.1 and 17.3% respectively. Hepatitis B viral infection among tuberculosis patients was associated with alcohol, sex, HIV, chronic illness. Hepatitis C viral infection among tuberculosis patients was associated with alcohol, sex, HIV, chronic illness. The incidence density for liver toxicity among tuberculosis patients was 843/15707 person-months and liver toxicity was determined by HIV, Hepatitis B, Hepatitis C, the severity of tuberculosis and chronic illnesses.ConclusionDecision-makers should consider incorporating screening for hepatitis B and C viral infection during tuberculosis treatment.
Highlights
This study was conducted to estimate the prevalence, determinants of hepatitis B, hepatitis C and the survival of tuberculosis patients until drug-induced hepatitis
In Ethiopia, 8% of the total population was infected with hepatitis B and 1.9% of the community was infected with hepatitis C virus [15, 16]
The prevalence of hepatitis B viral infection among tuberculosis patients was 15.1% [95% Confidence interval (CI): 13.92 - 16.28%]
Summary
This study was conducted to estimate the prevalence, determinants of hepatitis B, hepatitis C and the survival of tuberculosis patients until drug-induced hepatitis. Hepatitis is an inflammation of the liver cells called hepatocyte and, most commonly caused by hepatitis viruses. The severe form of hepatitis is caused by hepatitis B and hepatitis C viruses [1]. The prevalence of hepatitis B viral infection among tuberculosis patients ranges from 0.5 to 44% [8,9,10,11]. Hepatitis C virus burden among tuberculosis patients ranges from 3.4 - 44.6% [12,13,14]. In Ethiopia, 8% of the total population was infected with hepatitis B and 1.9% of the community was infected with hepatitis C virus [15, 16]. There is no evidence on tuberculosis hepatitis B and C co-infection rate in Ethiopia
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
